Wayland Group (CSE-WAYL) (OTCQB-MRRCF) Making Investors Happy as Price Climbs, Put on Your Watchlist Now

3683
Wayland Group - CSE-WAYL

Wayland Group (CSE:WAYL) (FRANKFURT: 75M) (OTCQB:MRRCF) (“Wayland,” formerly known as Maricann Group Inc.)

 

Wayland Group is a vertically-integrated cannabis cultivator and processor. Founded in 2013, the company is based in Burlington, Ontario, Canada and Munich, Germany, and has production facilities and operations in Canada (Langton, Ontario), Germany (Dresden, Saxony, Germany), and Switzerland (Regensdorf).

In early November 2018, Wayland announced an acquisition in Colombia and a joint venture in Italy, adding to its impressive EU footprint which also includes a production license in Malta.

Building on its robust established platform in Canada, Wayland is strategically assembling an array of valuable international assets in key leading Western European countries, giving Wayland a critical early-mover advantage in enormous but largely-untapped EU markets.

Canada

Wayland arrived early to the Canadian market, receiving its first license from Health Canada in March 2014. At its Langton, Ontario facility scheduled to be fully operational in Q4 2018, the company has 189,000 square feet of grow and production with annual capacity to grow up to 66,000 kg, with a phase 2 expansion of an additional 635,000 square feet of grow space to bring annual capacity to over 100,000 kg, to a phase 3 full buildout of 942,000 total square feet of cultivation and support facilities.

The company has entered agreements to supply and has allocated capacity in four Canadian provinces: British Columbia (3,622 kg), Alberta (3,375 kg), Manitoba (550 kg) and Ontario (37 Ontario Cannabis Store listings). The Langton facility is a low-cost, high-energy facility with a natural gas well and cogeneration facility on site, and all water recycled through a bio-pond.

On October 17, 2018, Wayland announced the release of its brand portfolio. Rather than taking a one-size-fits-all approach, the company took a purposeful, consumer-centric approach validated by consumer research and created brands designed to address various segments of the market. Wayland’s brands include KIWI (light users looking to better understand cannabis), HIGH TIDE (high-THC cannabis strains for experienced medium to heavy users), and NORTHERN HARVEST (light to medium users who enjoy cannabis), and soon-to-come LOST AT SEED (meticulously curated collection of the finest and most rare cannabis genetics), SOLARA C (highest quality CBD products), and RARA DANKNESS (selection of premium award-winning limited-edition strains).

Wayland is an exclusive provider of medical cannabis to Lovell Drugs, Ontario’s oldest pharmacy supply chain. The company also has a Canada-wide pharmacy partnership, which includes a comprehensive online education platform that will be available to pharmacists in over 2,100 Canadian pharmacies.

In 2017, Wayland entered a joint venture with Colorado-based Evolab Extraction Technologies, a leading extraction technology company, to produce pharmaceutical-grade cannabis concentrates. Wayland also acquired NanoLeaf, a biotech company with licensing rights to a number of patented drug delivery formulations, including Vesisorb, the first cannabinoid standardized-dose soft gel capsule in a nano-dispersed drug, developed at the Zurich Institute of Technology, that improves the bioavailability of cannabinoids without molecular structure changes.

 

WAYL Wayland Group

Looking Beyond Canada

Building on its success in Canada, Wayland has focused on Europe as an important market for cannabis with over 742 million people and combined gross domestic product of EUR 15.3 trillion with the cannabis market forecast to be worth EUR 115.7 billion by 2028. Drawing on its experience with EU-GMP certification of its Canadian facilities, Wayland is familiar with and able to navigate the strict European regulatory framework and complex licensing process. Wayland is using its experience in Canada to position itself as a market leader in Europe.

Germany

Wayland was one of the first Canadian companies involved in the German market. Wayland is developing a facility in Ebersbach, near Dresden, with a proposed 820,000 square feet of clean-room cultivation, processing, and extraction, including up to 300,000 square feet of cultivation. Cultivation and production licensing are subject to German government approval.

On October 15, 2018, Wayland announced an agreement to supply a minimum of 9,000 kg of EU-GMP certified cannabis dry flower over a three-year term to Cannamedical Pharma GmbH, an importer and distributor of cannabis in Germany to over 2,200 pharmacies. The first shipment is scheduled for December of 2018.

Wayland is also engaged in hemp operations in Germany through its European nutraceutical subsidiary MariPlant. On August 3, 2018, MariPlant commenced the harvest of approximately 405 acres of hemp.

Switzerland

Wayland recognized that Switzerland will also be a key market for the European cannabis industry. On May 10, 2018, the company announced the acquisition of Haxxon AG, positioning Wayland to operate in the Swiss market through Haxxon’s production of feminized high-CBD cannabis plants. Haxxon has a 64,500 square foot facility in Regensdorf, Switzerland, a suburb of Zurich. According to CEO Ben Ward: “A phenomenon has occurred in Switzerland, where people are substituting or modifying tobacco consumption with low THC cannabis (less than 1% THC).”

Italy

In Italy, Wayland entered a strategic partnership to take advantage of the country’s increasing acceptance of medical cannabis. On November 9, 2018, the company announced a joint venture agreement with CBD Italian Factory S.S., a company of Group San Martino, for the production of high-quality cannabis products in Italy. Pairing world-leading technology by Rockwell Automation with existing infrastructure in Piedmont , which includes agricultural expertise and biogas electricity, the company can sustainably produce CBD and THC products from a naturally-derived fuel source.

The joint venture will be split between Wayland (50.1%) and CBD Italian Factory (49.9%). A key aspect of the joint venture is a relationship with the University of Eastern Piedmont, which will develop a research center focusing on producing high-CBD products for medical purposes, and further studies of high-THC content and medical uses.

Colombia

As lowering cannabis production costs becomes increasingly important with increased competition, Wayland has entered Colombia as a low-cost source for its cannabis offerings in Europe. On November 6, 2018, the company announced an agreement to acquire Colma Pharmaceutical SAS, a licensed producer of THC cannabis in Colombia, holding four licenses for cultivation and processing in Ibague.

Wayland expects to cultivate THC cannabis outdoor and year-round with an infrastructure investment including 415,000 square feet of processing and clone and vegetation greenhouse facilities to support outdoor cannabis flower production on 300 acres. Wayland plans for initial crude extraction to be completed in Colombia and exported for further distillation in Wayland’s facilities in Germany, allowing Wayland to create a complete range of isolates of cannabinoids adding a sustainable supply for extraction and further distillation of cannabinoids.

CEO Ben Ward explained the Company’s move to low-cost, high-yield production in Colombia: “Our move to outdoor cultivation in Colombia is the first step in creating a reliable and consistent mass supply of cannabinoid isolates for the global market, including THC and CBD, and importantly commercial quantities of lesser known CBG and CBN.”

Mr. Ward further explained that Wayland’s acquisition in Colombia reflects the company global ambitions centered in Germany: “We will be establishing a robust outdoor flowering operation as a source of products to be manufactured for global distribution from Ebersbach, Germany. We continue to move aggressively in the international market, creating a global presence, built on a rational business platform of geographic cost centers.”

Malta

To complement its Western European assets, Wayland also received a license in Malta to manufacture finished-dose medical cannabis. This license allows Wayland to supply its Maltese operation with raw materials that will then undergo advanced post processing to create pure cannabis distillates, allowing for pharmaceutical manufacturing.

 

Chart appears to show solid support around $1.20 and steady climb to next resistance point around $1.68      

Any push past $1.68 could trigger massive gains. 

 

WAYL STOCK

Positioned for Growth

The valuations of Canadian licensed producers have been recently facing a reckoning. With the hype of impending legalization in the rear-view mirror, companies will need to distinguish themselves with real earnings and by executing on thoughtful strategies for the future. Wayland has recognized the early-mover opportunity to use its early success in Canada as a springboard for global ambitions. The company is executing on those ambitions.

Wayland presently trades at less than 30 percent of its January 23, 2018 high of $4.25 CAD, and significantly lower than its 200-day, 100-day, 50-day, and 20-day moving averages. As the market continues to distinguish between Canadian cannabis companies competing for slices of a relatively small Canadian market and those with global growth strategies and executable international footprints, Wayland is positioned for significant upside. Wayland’s focus on strategic expansion from its European hub in Germany and its tremendous Dresden-area facility to enter other significant EU markets bodes well for long-term significant growth.


Disclaimer :

This is a paid advertisement and all individuals should verify all claims and perform their own due diligence on ​​​WAYL (and / or any other mentioned companies and / or securities), and read this disclaimer in its entirety.

Small Cap Exclusive profiles are not a solicitation or recommendation to buy, sell or hold securities. Small Cap Exclusive is a paid advertiser and is not offering securities for sale. Neither Small Cap Exclusive nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by Small Cap Exclusive its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations.

Small Cap Exclusive does not recommend that the securities profiled should be purchased, sold or held and is not liable for any investment decisions by its readers or subscribers.

Information presented by Small Cap Exclusive may contain “forward-looking statements ” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance, are not statements of historical fact and may be “forward-looking statements.” Forward-looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements may be identified through the use of words such as “expects, ” “will, ” “anticipates,” “estimates,” “believes,” “may,” or by statements indicating that certain actions “may,” “could,” or “might” occur.

THIS SITE IS PROVIDED BY SMALL CAP EXCLUSIVE ON AN “AS IS” AND “AS AVAILABLE” BASIS. SMALL CAP EXCLUSIVE MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, AS TO THE OPERATION OF THIS SITE OR THE INFORMATION, CONTENT, MATERIALS, OR PRODUCTS INCLUDED ON THIS SITE. YOU EXPRESSLY AGREE THAT YOUR USE OF THIS SITE IS AT YOUR SOLE RISK.

TO THE FULL EXTENT PERMISSIBLE BY APPLICABLE LAW, SMALL CAP EXCLUSIVE DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. SMALL CAP EXCLUSIVE DOES NOT WARRANT THAT THIS SITE, IT’S SERVERS, OR E-MAIL SENT FROM SMALL CAP EXCLUSIVE ARE FREE OF VIRUSES OR OTHER HARMFUL COMPONENTS. SMALL CAP EXCLUSIVE, ITS MEMBERS, MANAGERS, OWNERS, AGENTS, AND EMPLOYEES WILL NOT BE LIABLE FOR ANY DAMAGES OF ANY KIND ARISING FROM THE USE OF THIS SITE, INCLUDING, BUT NOT LIMITED TO DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, AND CONSEQUENTIAL DAMAGES.

CERTAIN STATE LAWS DO NOT ALLOW LIMITATIONS ON IMPLIED WARRANTIES OR THE EXCLUSION OR LIMITATION OF CERTAIN DAMAGES. IF THESE LAWS APPLY TO YOU, SOME OR ALL OF THE ABOVE DISCLAIMERS, EXCLUSIONS, OR LIMITATIONS MAY NOT APPLY TO YOU, AND YOU MIGHT HAVE ADDITIONAL RIGHTS.

By using Small Cap Exclusive, you agree, without limitation or qualification, to be bound by, and to comply with, these Terms of Use and any other posted guidelines or rules applicable.

The website contains links to other related World Wide Web Internet sites and resources. Small Cap Exclusive is not responsible for the availability of these outside resources, or their contents, nor does Small Cap Exclusive endorse nor is Small Cap Exclusive responsible for any of the contents, advertising, products or other materials on such sites. Under no circumstances shall Small Cap Exclusive be held responsible or liable, directly or indirectly, for any loss or damages caused or alleged to have been caused by use of or reliance on any content, goods or services available on such sites. Any concerns regarding any external link should be directed to its respective site administrator or webmaster.

You agree to indemnify and hold Small Cap Exclusive, its officers, directors, owners, agents and employees, harmless from any claim or demand, including reasonable attorneys fees, made by any third party due to or arising out of your use of the website, the violation of these Terms of Use by you, or the infringement by you, or other user of the website using your computer, of any intellectual property or other right of any person or entity. We reserve the right, at our own expense, to assume the exclusive defense and control of any matter otherwise subject to indemnification.

Small Cap Exclusive is owned and operated by JBN PARTNERS LLC, which is a US based corporation. We are paid advertisers, also known as stock touts or stock promoters, who disseminate favorable information (this “Article”) about publicly traded companies (the “Profiled Issuers”).

We publish the Information on our website, smallcapexclusive.com and in newsletters, text message alerts, audio services, live interviews, featured “research” reports, on message boards and in email communications for specific time periods that are agreed upon between us and the Profiled Issuer and / or third party paying us. Our publication of the Information is known as a “Campaign”. This information may be sent to potential investors at different times that are minutes, hours, days or even weeks apart. Typically, the trading volume and price of a Profiled Issuer’s securities increases after the information is provided to the first group of investors. Therefore, the later an investor receives the Information, the more likely it is that he will suffer trading losses if they purchase the securities of a Profiled Issuer late in a Campaign. We are paid to advertise the Profiled Issuers, ROK Marketing Inc. Small Cap Exclusive has been hired by ​ROK Marketing Inc for a period beginning on ​​November 20, 2018 to publicly disseminate information about (​​WAYL) via website and email. We have been compensated $75,000. We will update any changes to our compensation. We own zero shares of (​​WAYL).

Third Parties paying us to market the Profiled Issuer we believe intend to sell their shares they hold while we tell investors to purchase during the Campaign. ​International Cobalt is a penny stock that was illiquid (little to no trading volume) prior to our Campaign, and therefore these securities are subject to wide fluctuations in trading price and volume. During the Campaign the trading volume and price of the securities of each Profile Issuer will likely increase significantly because of the media exposure. When the Campaign ends, the volume and price of the Profiled Issuer will likely decrease dramatically. As a result, investors who purchase during the Campaign and hold shares of the Profiled Issuer when the Campaign ends will probably lose most, if not all, of their investment.

The Information we publish in the Campaign is only a snapshot that provides only positive information about the Profiled Issuers. The Information consists of only positive content. We do not and will not publish any negative information about the Profiled Issuers; accordingly, investors should consider the Information to be one-sided and not balanced, complete, accurate, truthful and / or reliable. We do not verify or confirm any portion of the Information. We do not conduct any due diligence, nor do we research any aspect of the Information including the completeness, accuracy, truthfulness and / or reliability of the Information. We do not review the Profiled Issuers’ financial condition, operations, business model, management or risks involved in the Profiled Issuer’s business or an investment in a Profiled Issuer’s securities.

All information in our Campaign is publicly available information from 3rd party sources and / or the Profiled Issuers and/or the 3rd parties that hire us. We may also obtain the Information from publicly available sources such as the OTC Markets, Google, NASDAQ, NYSE, Yahoo, Bing, the Securities and Exchange Commission’s Edgar database or other available public sources.

We select the stocks we profile and / or pick as we are compensated to advertise them. If an investor relies solely on the Information in making an investment decision it is highly probable that the investor will lose most, if not all, of his or her investment. Investors should not rely on the Information to make an investment decision.

The source of our compensation varies depending upon the particular circumstances of the Campaign. In certain cases, we are compensated by the Profiled Issuers, third party shareholders, and / or other parties related to the Profiled Issuers such as officers and/or directors who will derive a financial or other benefit from an increase in the trading price and/or volume of a Profiled Issuer’s securities.

We make no warranty and / or representation about the Information, including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the Information is at your own risk. The Information is provided as is without limitation.

We are not, and do not act in the capacity of any of the following; as such, you should not construe our activities as involving any of the following: an independent adviser or consultant; a fortune teller; an investment adviser or an entity engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal and / or state level; a broker-dealer or an individual acting in the capacity of a registered representative or broker; a stock picker; a securities trading expert; a securities researcher or analyst; a financial planner or one who engages in financial planning; a provider of stock recommendations; a provider of advice about buy, sell or hold recommendations as to specific securities; or an agent offering or securities for sale or soliciting their purchase.

There are numerous risks associated with each Profiled Issuer and investors should undertake a full review of each Profiled Issuer with the assistance of their financial, legal, and tax advisers prior to purchasing the securities of any Profiled Issuer.

We are not objective or independent and have multiple conflicts of interest. The Profiled Issuers and parties hiring us have conflicts of interest. Third parties that have hired us and own shares will sell these shares while we tell investors to purchase, and this selling of the Profiled Issuer’s securities will likely cause investors to suffer losses.

Our publication of the Information involves actual and material conflicts of interest including but not limited to the fact that we receive monetary compensation in exchange for publishing the (favorable) Information about the Profiled Issuers; and we do not publish any negative information, whatsoever, about the Profiled Issuers; in addition to the fact that while we do not own the Profiled Issuer’s securities, the third parties that hired us do, and intend to sell all of these securities during the Campaign while we publish favorable information that instructs investors to purchase, and this selling of the Profiled Issuer’s securities will likely cause investors to suffer losses.

We are not responsible or liable for any person’s use of the Information or any success or failure that is directly or indirectly related to such person’s use of the Information because we have specifically stated that the information is not reliable and should not be relied upon for any purpose. We are not responsible for omissions and / or errors in the Information and we are not responsible for actions taken by any person who relies upon the Information.

We urge Investors to conduct their own in-depth investigation of the Profiled Issuers with the assistance of their legal, tax and / or investment adviser(s). An investor’s review of the Information should include but not be limited to the Profiled Issuer’s financial condition, operations, management, products and / or services, trends in the industry and risks that may be material to the profiled Issuer’s business and other information he and his advisers deem material to an investment decision. An investor’s review should include, but not be limited to a review of available public sources and information received directly from the Profiled Issuers or from websites such as Google, Yahoo, Bing, OTC Markets, NASDAQ, NYSE, www.sec.gov or other available public sources.

We are providing you with this disclaimer because we are publishing advertisements about penny stocks. Because we are paid to disseminate the Information to the public about securities, we are required by the securities laws including Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose my compensation as well as other important information, This information includes that we may hold, as well as purchase and sell, the securities of a Profiled Issuer before, during and after we publish favorable Information about the Profiled Issuer. We may urge investors to purchase the securities of a Profiled Issuer while we sell my own shares. The anti-fraud provisions of federal and state securities laws require us to inform you that we may engage in buying and selling of Profiled Issuer’s securities before, during and after the Campaigns.

Any investment in the Profiled Issuers involves a high degree of risk and uncertainty. The securities may be subject to extreme volume and price volatility, especially during the Campaigns. Favorable past performance of a Profiled Issuer does not guarantee future results. If you purchase the securities of the Profiled Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Profiled Issuers include, but are not limited to the risks stated below.

We do not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. We conduct no due diligence or investigation whatsoever of the Information or the Profiled Issuers and we do not receive any verification from the Profiled Issuer regarding the Information we disseminate.

If we publish any percentage gain of a Profiled Issuer from the previous day close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment.

The Information may contain statements asserting that a Profiled Issuer’s stock price has increased over a certain period of time which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon the (favorable) Information in your analysis of the present or future potential of a Profiled Issuer or its securities.

The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Profiled Issuer’s future stock price or future financial performance.

You may encounter difficulties determining what, if any, portions of the Information are material or non-material, making it all the more imperative that you conduct your own independent investigation of the Profiled Issuer and its securities with the assistance of your legal, tax and financial advisor.

When 3rd parties that hire us acquire, purchase and / or sell the securities of the Profiled Issuers, it may (a) cause significant volatility in the Profiled Issuer’s securities; (b) cause temporary but unrealistic increases in volume and price of the Profiled Issuer’s securities; (c) if selling, cause the Profiled Issuer’s stock price to decline dramatically; and (d) permit themselves to make substantial profits while investors who purchase during the Campaign experience significant losses.

The securities of the Profiled Issuers are high risk, unstable, unpredictable and illiquid which may make it difficult for investors to sell their securities of the Profiled Issuers.

We may hire third party service providers and stock promoters to electronically disseminate live news regarding the Profiled Issuers, yet we have no control over the content of and do not verify the information that the Profiled Issuers and/or third party service providers publish. These third party service providers are likely compensated for providing positive information about the Issuer and may fail to disclose their compensation to you.

If a Profiled Issuer is a SEC reporting company, it could be delinquent (not current) in its periodic reporting obligations (i.e., in its quarterly and annual reports), or if it is an OTC Markets Pink Sheet quoted company, it may be delinquent in its Pink Sheet reporting obligations, which may result in OTC Markets posting a negative legend pertaining to the Profiled Issuer at www.otcmarkets.com, as follows: (i) “Limited Information” for companies with financial reporting problems, economic distress, or that are unwilling to file required reports with the Pink Sheets; (ii) “No Information,” which characterizes companies that are unable or unwilling to provide any disclosure to the public markets, to the SEC or the Pink Sheets; and (iii) “Caveat Emptor,” signifying buyers should be aware that there is a public interest concern associated with a company’s illegal spam campaign, questionable stock promotion, known investigation of a company’s fraudulent activity or its insiders, regulatory suspensions or disruptive corporate actions.

If the Information states that a Profiled Issuer’s securities are consistent with the future economic trends or even if your independent research indicates that, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and/or government may react in unforeseen ways and be affected by behavioral biases that we are unable to predict; (c) human and social factors may outweigh future economic trends that we state may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of new circumstances and situations in which uncertainty becomes reality rather than predicted economic outcome; or (f) if the trend predicted involves a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies.

The Information is presented only as a brief snapshot of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities. You should consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.otcmarkets.com or other electronic media, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the OTCMarkets.com; (c) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.org. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative legends and designations at otcmarkets.com.

Small Cap Exclusive , reserves the right, at its sole discretion, to change, modify, add and/ or remove all or part of this Disclaimer and / or Terms of Use at any time.